RxDoctor Payments Data

Marco Chavez, MD

Family Medicine · Longview, TXNPI 1033566435

Payments from drug & device makers

$9,345in general payments, 2019–2025

Across 656 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Pfizer$825
  • GSK$741
  • Lilly USA, LLC$594
  • Amgen$565
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,331100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,345 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$339,938
Medicare patients
320
Services billed
14,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide185$259,577
JardianceEmpagliflozin142$213,983
MounjaroTirzepatide192$209,476
EliquisApixaban92$100,158
FarxigaDapagliflozin Propanediol48$63,042
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog58$49,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$43,112
TrulicityDulaglutide27$39,769
JanuviaSitagliptin Phosphate19$26,031
MyrbetriqMirabegron11$14,337
XareltoRivaroxaban11$11,281
Breo ElliptaFluticasone/Vilanterol20$9,477
Atorvastatin Calcium664$6,214
Spiriva RespimatTiotropium Bromide11$5,485
SymbicortBudesonide/Formoterol Fumarate15$4,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,139$259,577185 claims
Lilly USA, LLCMounjaro, Trulicity$594$249,245219 claims
Boehringer IngelheimJardiance, Spiriva Respimat$553$219,468153 claims
PfizerEliquis$825$100,15892 claims
AstraZenecaFarxiga, Symbicort$488$67,74763 claims
GSKTrelegy Ellipta, Breo Ellipta$741$52,58974 claims
MerckJanuvia$379$26,03119 claims
Astellas Pharma US IncMyrbetriq$248$14,33711 claims
Johnson & JohnsonXarelto$120$11,28111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →